Patent · US Active

Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies

US11987644B2 · kind B2 · utility

0Cited by

5References

4Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michael Bardroff · Soest, DE
Tina BUCH · Holmfield Drive, DE
Christian GRAF · Munich, DE
Daniel HEITMANN · Zürich, CH
Thomas Jostock · Neuenburg am Rhein, DE
Hans-Peter Knopf · Schallstadt, DE
Rolf KOEHLER · Basel, CH
Jiri KOVARIK · Bellinzona, CH
Stephen John Oliver · Basel, CH
Dhavalkumar Patel · Durham, US
Maximilian Woisetschlaeger · Oberwil, CH

Key dates

Filing date	Apr 9, 2020
Grant date	May 21, 2024
Priority date	—
Expiry date	Apr 9, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.